Epigenetic age acceleration (EAA) refers to the extent to which an individual's biological age, estimated from DNA methylation patterns, exceeds their chronological age, indicating accelerated cellular and tissue aging.
Objective
We investigated the association between EAA and Alzheimer's disease (AD), with a focus on sex-based differences.
Methods
EAA was estimated from blood samples in 127 participants with Alzheimer's disease-related cognitive impairment (ADCI) and 143 cognitively unimpaired (CU) participants, recruited from a nationwide multicenter study under the Precision Medicine Platform for Mild Cognitive Impairment (PREMIER) consortium in Korea.
Results
EAA measures indicated higher acceleration in the ADCI group compared to the CU group, particularly for extrinsic epigenetic age acceleration (EEAA), AgeAccelResidualHannum, and AgeAccelPheno. Sex-specific analyses revealed that EEAA significantly differed between the ADCI and CU groups in both men and women, with a greater EEAA in men. Logistic regression analysis demonstrated that increased EEAA, the presence of APOE ɛ4 allele, and poorer nutritional status were significantly associated with a higher likelihood of ADCI. EEAA increased ADCI risk more strongly in men than in women, whereas chronological age showed a protective effect only in women.
Conclusions
As a marker of immune system aging, EEAA may be associated with ADCI. These findings suggest that EEAA serves as a complementary indicator of systemic biological aging within the AD spectrum. The greater EAA observed in men was consistently present in ADCI, highlighting the importance of considering sex differences in EAA-related AD research.
MontineTJPhelpsCHBeachTG, et al.National institute on aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol2012; 123: 1–11.
2.
HorvathSRajK. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet2018; 19: 371–384.
3.
HouYDanXBabbarM, et al.Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol2019; 15: 565–581.
4.
HorvathS. DNA Methylation age of human tissues and cell types. Genome Biol2013; 14: R115.
5.
LevineMELuATBennettDA, et al.Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer's disease related cognitive functioning. Aging (Albany NY)2015; 7: 1198–1211.
6.
GrodsteinFLemosBYuL, et al.The association of epigenetic clocks in brain tissue with brain pathologies and common aging phenotypes. Neurobiol Dis2021; 157: 105428.
7.
SugdenKCaspiAElliottML, et al.Association of pace of aging measured by blood-based DNA methylation with age-related cognitive impairment and dementia. Neurology2022; 99: e1402–e1413.
8.
ConinxEChewYCYangX, et al.Hippocampal and cortical tissue-specific epigenetic clocks indicate an increased epigenetic age in a mouse model for Alzheimer's disease. Aging (Albany NY)2020; 12: 20817–20834.
9.
MilicicLVacherMPorterT, et al.Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. Geroscience2022; 44: 1807–1823.
10.
FransquetPDLacazePSafferyR, et al.Accelerated epigenetic aging in peripheral blood does not predict dementia risk. Curr Alzheimer Res2021; 18: 443–451.
11.
InksterAMDuarte-GutermanPAlbertAY, et al.Are sex differences in cognitive impairment reflected in epigenetic age acceleration metrics?Neurobiol Aging2022; 109: 192–194.
RahmanASchelbaumEHoffmanK, et al.Sex-driven modifiers of Alzheimer risk: a multimodality brain imaging study. Neurology2020; 95: e166–e178.
14.
KimSKimMJKimS, et al.Gender differences in risk factors for transition from mild cognitive impairment to Alzheimer's disease: a CREDOS study. Compr Psychiatry2015; 62: 114–122.
15.
NebelRAAggarwalNTBarnesLL, et al.Understanding the impact of sex and gender in Alzheimer's disease: a call to action. Alzheimers Dement2018; 14: 1171–1183.
16.
MazureCMSwendsenJ. Sex differences in Alzheimer's disease and other dementias. Lancet Neurol2016; 15: 451–452.
17.
FerrettiMTIulitaMFCavedoE, et al.Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol2018; 14: 457–469.
18.
FerrettiMTMartinkovaJBiskupE, et al.Sex and gender differences in Alzheimer's disease: current challenges and implications for clinical practice: position paper of the dementia and cognitive disorders panel of the European academy of neurology. Eur J Neurol2020; 27: 928–943.
19.
CrimminsEMThyagarajanBLevineME, et al.Associations of age, sex, race/ethnicity, and education with 13 epigenetic clocks in a nationally representative U.S. Sample: the health and retirement study. J Gerontol A Biol Sci Med Sci2021; 76: 1117–1123.
20.
LiXPlonerAWangY, et al.Longitudinal trajectories, correlations and mortality associations of nine biological ages across 20-years follow-up. Elife2020; 9: e51507.
21.
KankaanpaaATolvanenASaikkonenP, et al.Do epigenetic clocks provide explanations for sex differences in life span? A cross-sectional twin study. J Gerontol A Biol Sci Med Sci2022; 77: 1898–1906.
22.
EngelbrechtHRMerrillSMGladishN, et al.Sex differences in epigenetic age in Mediterranean high longevity regions. Front Aging2022; 3: 1007098.
23.
JangHShinDKimY, et al.Korea-Registries to overcome dementia and accelerate dementia research (K-ROAD): a cohort for dementia research and ethnic-specific insights. Dement Neurocogn Disord2024; 23: 212–223.
24.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
25.
PetersenRCSmithGEWaringSC, et al.Mild cognitive impairment: clinical characterization and outcome. Arch Neurol1999; 56: 303–308.
26.
ChinJParkJYangSJ, et al.Re-standardization of the Korean-instrumental activities of daily living (K-IADL): clinical usefulness for various neurodegenerative diseases. Dement Neurocogn Disord2018; 17: 11–22.
27.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
28.
KimJJahngSKimS, et al.A comparison of item characteristics and test information between the K-MMSE∼2:sV and K-MMSE. Dement Neurocogn Disord2024; 23: 117–126.
29.
KangYNaDL. Seoul Neuropsychological Screening Battery. Incheon: Human Brain Research & Consulting Co., 2003.
30.
AhnHJChinJParkA, et al.Seoul Neuropsychological screening battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci2010; 25: 1071–1076.
31.
GuigozY. The Mini nutritional assessment (MNA) review of the literature–what does it tell us?J Nutr Health Aging2006; 10: 466–485; discussion 485–467.
32.
LeeSKimWChangS, et al.The use of the Korean version of short form geriatric depression scale (SGDS-K) in the community dwelling elderly in Korea. J Korean Geriatr Psychiatry2013; 17: 37–43.
33.
CraigCLMarshallALSjostromM, et al.International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc2003; 35: 1381–1395.
34.
SeibylJCatafauAMBarthelH, et al.Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: results from a phase-3 study. J Nucl Med2016; 57: 900–906.
35.
CollijLESalvadoGShekariM, et al.Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur J Nucl Med Mol Imaging2021; 48: 2169–2182.
JohnsonWELiCRabinovicA. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics2007; 8: 118–127.
38.
HannumGGuinneyJZhaoL, et al.Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell2013; 49: 359–367.
39.
LuATQuachAWilsonJG, et al.DNA Methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY)2019; 11: 303–327.
40.
BelskyDWCaspiACorcoranDL, et al.DunedinPACE, a DNA methylation biomarker of the pace of aging. Elife2022; 11: e73420.
41.
DegermanSJosefssonMNordin AdolfssonA, et al.Maintained memory in aging is associated with young epigenetic age. Neurobiol Aging2017; 55: 167–171.
42.
ZhangMTartagliaMCMorenoD, et al.DNA Methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients. Acta Neuropathol2017; 134: 271–279.
43.
ElliottHRBurrowsKMinJL, et al.Characterisation of ethnic differences in DNA methylation between UK-resident south asians and europeans. Clin Epigenetics2022; 14: 130.
44.
El KhouryLYGorrie-StoneTSmartM, et al.Systematic underestimation of the epigenetic clock and age acceleration in older subjects. Genome Biol2019; 20: 283.
45.
BeydounMAShakedDTajuddinSM, et al.Accelerated epigenetic age and cognitive decline among urban-dwelling adults. Neurology2020; 94: e613–e625.
46.
QuachALevineMETanakaT, et al.Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. Aging (Albany NY)2017; 9: 419–446.
47.
MittelbrunnMKroemerG. Hallmarks of T cell aging. Nat Immunol2021; 22: 687–698.
48.
PereiraBIDe MaeyerRPHCovreLP, et al.Sestrins induce natural killer function in senescent-like CD8(+) T cells. Nat Immunol2020; 21: 684–694.
49.
Desdin-MicoGSoto-HerederoGArandaJF, et al.T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science2020; 368: 1371–1376.
50.
MogilenkoDAShpynovOAndheyPS, et al.Comprehensive profiling of an aging immune system reveals clonal GZMK(+) CD8(+) T cells as conserved hallmark of inflammaging. Immunity2021; 54: 99–115 e112.
51.
HenekaMTCarsonMJEl KhouryJ, et al.Neuroinflammation in Alzheimer's disease. Lancet Neurol2015; 14: 388–405.
52.
WalkerKAChenJZhangJ, et al.Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. Nat Aging2021; 1: 473–489.
53.
ShenXNNiuLDWangYJ, et al.Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry2019; 90: 590–598.
54.
WalkerKAGrossALMoghekarAR, et al.Association of peripheral inflammatory markers with connectivity in large-scale functional brain networks of non-demented older adults. Brain Behav Immun2020; 87: 388–396.
55.
FaniLGeorgakisMKIkramMA, et al.Circulating biomarkers of immunity and inflammation, risk of Alzheimer's disease, and hippocampal volume: a Mendelian randomization study. Transl Psychiatry2021; 11: 291.
56.
PagoniPKorologou-LindenRSHoweLD, et al.Causal effects of circulating cytokine concentrations on risk of Alzheimer's disease and cognitive function. Brain Behav Immun2022; 104: 54–64.
57.
TsuiADavisD. Systemic inflammation and causal risk for Alzheimer's dementia: possibilities and limitations of a Mendelian randomization approach. Aging Med (Milton)2018; 1: 249–253.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
